Pharmaceuticals New Zealand

New Zealand RNA Interference Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $49.7 Mn Placeholder estimate
Estimate 2025 $59.8 Mn 1% of the global market
Projected 2034 $315.4 Mn 427.7% Adds $255.6 Mn over 9 forecast years
CAGR 2025–2034 20.3% Faster than 87% of 160 Pharmaceuticals markets here
Key players 5
  • New Zealand is 1.04% of the global market.
  • In APAC, the largest is China at $461.5 Mn.
  • Fastest growing: India at 23% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$255.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
RNA Interference Therapeutics Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $49.7 Mn — —
2025 (base) $59.8 Mn +$10.1 Mn —
2026 (forecast) $71.9 Mn +$12.1 Mn +20.3%
2027 (forecast) $86.5 Mn +$14.6 Mn +44.7%
2028 (forecast) $104.1 Mn +$17.6 Mn +74.1%
2029 (forecast) $125.2 Mn +$21.1 Mn +109.4%
2030 (forecast) $150.6 Mn +$25.4 Mn +152%
2031 (forecast) $181.2 Mn +$30.6 Mn +203.1%
2032 (forecast) $217.9 Mn +$36.8 Mn +264.6%
2033 (forecast) $262.2 Mn +$44.2 Mn +338.7%
2034 (forecast) $315.4 Mn +$53.2 Mn +427.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand RNA Interference Therapeutics Market Analysis at a glance
Market size, 2025$59.8 Mn placeholder estimate
Forecast, 2034$315.4 Mn placeholder estimate
Growth (CAGR), 2025–203420.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsMolecule, indication and end user (see all)
Key playersAlnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis AG, Dicerna (Novo Nordisk) (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
Active clinical trials3 in New ZealandSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand RNA Interference Therapeutics Market Analysis Executive Summary

RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.

Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).

Bar chart: New Zealand RNA Interference Therapeutics market size, 2024–2034, placeholder estimates. $49.7 Mn in 2024, $59.8 Mn in 2025 and $315.4 Mn in 2034, 20.3% CAGR.
New Zealand RNA Interference Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand RNA Interference Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for RNA Interference Therapeutics Market in New Zealand

The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RNA Interference Therapeutics Market in New Zealand

RNA Interference Therapeutics in New Zealand: rules, payment and research

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2] ClinicalTrials.gov lists 3 studies on RNA Interference Therapeutics that are recruiting, active or about to start in New Zealand.⁠[3]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RNA Interference Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RNA Interference Therapeutics in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the RNA Interference Therapeutics market in New Zealand?
Placeholder estimate: about $59.8 Mn in 2025, rising to about $315.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RNA Interference Therapeutics market in New Zealand growing?
Placeholder estimate: about 20.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RNA Interference Therapeutics market report cover?
The report splits the market by molecule (siRNA, Antisense Oligonucleotides, microRNA), indication (Rare Genetic Diseases, Cardiovascular, Liver Diseases, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RNA Interference Therapeutics market?
Key players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis AG and Dicerna (Novo Nordisk).
What is driving the RNA Interference Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
Who regulates RNA Interference Therapeutics in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How many clinical trials on RNA Interference Therapeutics are running in New Zealand?
3 studies are recruiting, active or about to start in New Zealand, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
How much research is published on RNA Interference Therapeutics?
PubMed lists 28 papers on RNA Interference Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on biologics and biosimilars and genomics

See the topic